Bevacizumab biosimilar is under clinical development by Aurobindo Pharma and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bevacizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bevacizumab biosimilar overview

Bevacizumab biosimilar is under development for the treatment of metastatic colon cancer, metastatic rectal cancer, cervical cancer, ovarian cancer, peritoneal cancer, kidney cancer (renal cell cancer), glioblastoma multiforme, breast cancer, non-squamous and non-small cell lung cancer. It is administered through intravenous route. The drug candidate acts by targeting the human vascular endothelial growth factor A (VEGF-A).

Aurobindo Pharma overview

Aurobindo Pharma (Aurobindo) is a vertically integrated pharmaceutical company that manufactures and markets generic pharmaceuticals and active pharmaceutical ingredients (APIs). Its product portfolio is spread across major therapeutic and product categories including antibiotics, anti-retroviral, systemic gastroenterological, central nervous system, cardiovascular, anti-allergies, anti-diabetics, other therapeutic areas. The company also produces novel proprietary biocatalysts, vitamins, minerals, dietary supplements, sports nutrition, functional foods, weight loss products and fermentation-based semi-synthetic products. Aurobindo operates manufacturing facilities in India, Brazil, Portugal and the US; and R&D facilities in India and the US. The company exports products to several countries worldwide. Aurobindo is headquartered in Hyderabad, Telangana, India.

For a complete picture of Bevacizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.